<--- Back to Details
First PageDocument Content
PARP inhibitor / Autoimmune diseases / Olaparib / Poly ADP ribose polymerase / Ankylosing spondylitis / TNF inhibitor / Targeted therapy / Non-steroidal anti-inflammatory drug / Disease-modifying antirheumatic drug / Medicine / Biology / Pharmacology
Date: 2015-03-05 09:09:56
PARP inhibitor
Autoimmune diseases
Olaparib
Poly ADP ribose polymerase
Ankylosing spondylitis
TNF inhibitor
Targeted therapy
Non-steroidal anti-inflammatory drug
Disease-modifying antirheumatic drug
Medicine
Biology
Pharmacology

March[removed]Making a difference with chemistry You may enjoy studying chemistry, but how can you use it to make a difference

Add to Reading List

Source URL: www.hoddereducation.co.uk

Download Document from Source Website

File Size: 1,26 MB

Share Document on Facebook

Similar Documents

Dries 1 Annika Dries Human Biology 158G Final Project 6 December 2013 The PARP inhibitor: the promises and challenges of targeted breast cancer therapy

Dries 1 Annika Dries Human Biology 158G Final Project 6 December 2013 The PARP inhibitor: the promises and challenges of targeted breast cancer therapy

DocID: 1uCeV - View Document

Theranostics 2016, Vol. 6, IssueIvyspring

Theranostics 2016, Vol. 6, IssueIvyspring

DocID: 1q5FE - View Document

The DNA damage response in tumorigenesis and cancer treatment Jiri Bartek and Jiri Lukas The cellular DNA damage response (DDR) machinery is intimately linked with cancer as damage to DNA causes cancer. The DDR provides

The DNA damage response in tumorigenesis and cancer treatment Jiri Bartek and Jiri Lukas The cellular DNA damage response (DDR) machinery is intimately linked with cancer as damage to DNA causes cancer. The DDR provides

DocID: 1p16I - View Document

Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri

Final results of the phase I first-in-man trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carri

DocID: 1lhcT - View Document

Microsoft Word - BeiGene BGB 290 FPI Release_Final

Microsoft Word - BeiGene BGB 290 FPI Release_Final

DocID: 1anIY - View Document